Rationale Tramadol is a prescription analgesic that activates mu opioid and monoamine receptor systems. Tramadol is thought to have limited abuse potential compared to mu opioid agonists, but laboratory data indicate that it shares some of their pharmacodynamic effects. Objectives This study evaluated the effect of mu opioid receptor blockade with naltrexone on the pharmacodynamic action of tramadol in humans.
Introduction
Illicit use of prescription pain relievers is a persistent public health problem in the USA. More individuals over the age of 12 reported past month nonmedical use of prescription pain relievers (5.1 million people) than cocaine (1.5 million people), methamphetamine (353,000 people), or heroin (200,000 people) in 2010 [Substance Abuse and Mental Health Services Administration (SAMHSA), 2011]. Most prescription pain relievers used for nonmedical reasons are mu opioid agonists, (Manchikanti et al. 2010; Mello et al. 1981; SAMHSA 2007 SAMHSA , 2009 ; Sullivan et al. 2006; Walsh et al. 1996) .
Tramadol produces its analgesic effects, in part, through its monaminergic activity in contrast to prototypic opioid analgesics (Epstein et al. 2006; Grond and Sablotzki 2004) . Prior to the US Food and Drug Administration (FDA) approval of tramadol for use in mild-to-moderate pain, it had widespread use in Germany with few cases of reported abuse (Radbruch et al. 1996 ). An early human laboratory abuse liability study with parenteral tramadol also indicated that it had limited abuse potential compared to morphine (Preston et al. 1991) . These data and the German experience likely played a significant role in the US decision to approve tramadol as an unscheduled substance. However, since tramadol's approval in the USA, there have been reports of its abuse and misuse (Cicero et al. 2005; Schneider et al. 2009 ). These data have led to some individual states, including Kentucky and Arkansas, placing tramadol on the list of controlled substances. Tramadol is a racemic mixture. The + and − enantiomers of tramadol inhibit serotonin and norepinephrine reuptake, respectively (Matthiesen et al. 1998 ). These isomers bind only weakly to the mu opioid receptor, but are metabolized by cytochrome P450 2D6 (CYP2D6) enzymes into odesmethyltramadol (M1; Driessen et al. 1993; Frink et al. 1996; Gillen et al. 2000; Raffa et al. 1992; Stamer et al. 2007; Volpe et al. 2011 ). M1 has a comparatively higher affinity for the mu receptor than tramadol (Raffa et al. 1992; Volpe et al. 2011 ).
To date, preclinical studies suggest that the abuse-related behavioral effects of tramadol are similar to those of other full mu opioid receptor agonists, but generally of lesser magnitude. For example, rats and rhesus monkeys self-administer tramadol to a greater degree than vehicle, albeit less than has been observed with prototypic opioids (O'Connor and Mead 2010; Yanagita 1978) . Other preclinical research has shown that tramadol engenders significant conditioned place preference like morphine (Sprague et al. 2002; Tzschentke et al. 2002) and drug discrimination studies show cross-generalization between morphine and tramadol (Filip et al. 2004; Ren and Zheng 2000; Swedberg et al. 1988 Swedberg et al. , 1992 .
Clinical studies show similar results in that orally administered tramadol also produces some effects that overlap with prototypic opioid effects (Carroll et al. 2006; Duke et al. 2011; Jasinski et al. 1993; Lanier et al. 2010; Lofwall et al. 2007; Zacny 2005) . For instance, tramadol and oxycodone produced comparable increases in ratings of "Liking" (Jasinski et al. 1993) , single oral tramadol doses (200 and 400 mg) decreased opioid withdrawal among subjects physically dependent on morphine (Lofwall et al. 2007) , naloxone precipitated opioid withdrawal symptoms among subjects maintained on oral tramadol (Lanier et al. 2010) , and higher (but not lower) doses of tramadol substituted for hydromorphone in a drug discrimination procedure, but did not significantly increase positive subjective ratings (e.g., "Liking," "Good Effects") as did hydromorphone (Duke et al. 2011) .
The similarities between tramadol and prototypic mu opioids implicate the mu opioid receptor in the behavioral effects of tramadol. To determine more fully how activation of the mu opioid receptor influences its behavioral pharmacology, preclinical studies have tested the impact of mu opioid receptor blockade with naloxone or naltrexone on the effects of tramadol (Filip et al. 2004; Ren and Zheng 2000; Tzschentke et al. 2002) . Those studies showed that mu opioid receptor blockade attenuated discriminative stimulus and conditioned place preference effects of tramadol, suggesting that mu opioid receptor activation is primarily responsible for the behavioral effects of tramadol. To date, there are no published studies that have tested mu opioid receptor blockade on the acute pharmacodynamic effects of tramadol in non-dependent humans. This study sought to determine how naltrexone pretreatment influences the pharmacodynamic actions of tramadol. Thus, ten non-opioid dependent adults with recent histories of recreational opioid use completed an inpatient, double-blind, randomized, within-subject protocol whereby the effects of oral tramadol (0, 87.5, 175, and 350 mg) were assessed after pretreatment with oral placebo and naltrexone (50 mg). Oral hydromorphone (4 and 16 mg) served as a positive control. It was hypothesized that tramadol would produce effects comparable to hydromorphone but of lower magnitude and that naltrexone administration would attenuate the effects of both tramadol and hydromorphone.
Methods

Participants
Nonphysically dependent adult recreational opioid users were recruited and compensated for participation. Individuals seeking treatment for substance abuse or successfully sustaining abstinence were excluded. All participants were in good health verified by medical history and physical examination, an electrocardiogram (ECG) and laboratory tests. Persons with seizure disorders, asthma or other respiratory disorders, head injury, hypertension, cardiovascular disease, or an abnormal ECG were excluded. All participants reported illicit use of opioids, which was confirmed by urinalysis. The University of Kentucky Institutional Review Board approved the study. Participants gave their written informed consent; the consent document stated that oral placebo, tramadol, hydromorphone, and naltrexone would be administered. A Certificate of Confidentiality was obtained from the National Institute on Drug Abuse. The study was conducted in accordance with the Helsinki guidelines.
This inpatient study lasted approximately 6 weeks. Sessions were conducted at least 72 h apart (e.g., Monday and Thursday). Prior to each session, urine specimens and breath samples were obtained and tested for illicit drugs to ensure the absence of unauthorized substance use. Females were tested for pregnancy prior to each session. Participants fasted for 2 h and abstained from smoking cigarettes for 1 h prior to the start of sessions; they were not allowed to eat or smoke during sessions.
Drugs
All drugs were administered in random order. Tramadol (87.5, 175, and 350 mg; UDL Labs, Rockford, IL, USA), hydromorphone (4 and 16 mg; Halo Pharmaceuticals, Whippany, NJ, USA), and naltrexone (50 mg; Barr Labs, Pomona, NY, USA) were prepared by over-encapsulating drug with cornstarch filler in opaque gelatin capsules. Placebo capsules contained only cornstarch. The intermediate and high doses of tramadol were selected to match those used in a previous study (Jasinski et al. 1993) ; the low dose was selected so that a fourfold range of doses could be tested, including a dose in the therapeutic range. The hydromorphone doses were selected to be roughly equipotent to the low and high tramadol doses based on previous research (Jasinski et al. 1993; Walsh et al. 2008b ). The naltrexone dose was selected because it provides near complete mu opioid blockade (Lee et al. 1988; Walsh et al. 1996) . The first dose containing placebo or naltrexone was administered at approximately 9:00 AM (i.e., time point 0; Table 1 ). The second dose containing placebo, tramadol, or hydromorphone was administered 1 h later (i.e., time point 60; Table 1 ).
Study design
A double-blind, within-subject, placebo-controlled design was used. Twelve sessions were conducted at the University of Kentucky Clinical Research Development and Operations Center during which participants received one of the 12 possible dose combinations (i.e., placebo or 50 mg naltrexone combined with placebo, 87.5, 175, or 350 mg tramadol or 4 or 16 mg hydromorphone). Baseline data were collected for 30 min before (i.e., 8:30 AM) and continued for 7 h after drug administration (see Table 1 ).
Experimental sessions
Data collection techniques were similar to those described previously (Stoops et al. 2010) . Table 1 illustrates the data collection timeline for all measures. The dosing intervals and data collection time points were selected (1) to allow naltrexone to reach T max prior to the onset of expected opioid agonist effects and (2) to capture the onset, peak, and offset of effects of tramadol, M1, and hydromorphone.
Physiological measures Oxygen saturation, blood pressure, and heart rate were collected every minute, except during the Continuous Performance Task, using an automatic monitoring device (Scholar III model 507ELC2, Criticare Systems INC, Waukesha, WI, USA). Pupil diameter was determined with a pupillometer (PLR-200, NeurOptics, Irvine, CA, USA) in constant room lighting. Expired CO 2 (mm Hg) and respiratory rate (breaths/minute) were measured using a capnograph (N85, Nellcor, Boulder, CO, USA).
Subject-and observer-rated measures Subject-rated measures included a visual analog scale (VAS; Walsh et al. 2008b ), a Street Value Questionnaire, a Drug Identification Questionnaire, and a 51-item adjective checklist that encompassed an Opioid Agonist Scale and Withdrawal Scale (see Walsh et al. 1995 for those scale descriptions). Items sensitive to the effects of norepinephrine reuptake inhibitors (i.e., atomoxetine and desipramine; Heil et al. 2002; Jasinski et al. 2008 ) and serotonin reuptake inhibitors (Vanderkooy et al. 2002 ) also were included in this checklist. The items were "Abdominal Pain," "Agitated," "Bad," "Blurred Vision," "Decreasing Your Appetite," "Dizzy," "Drowsy," "Dry Mouth," "Fatigued or Lazy," "Flushing," "Headache," "Heavy or Sluggish Feeling," "Nervous," "Relaxed," "Sick," "Sleepy," "Stimulated," "Sweating," "Turning of Stomach," "Twitch," and "Weak," scored from 0 to 4 on a Likert-type scale. An observer-rated opioid agonist adjective rating scale also was used (Walsh et al. 2008b ).
Ocular and performance tasks The Maddox Wing ocular task (see Walsh et al. 2008b ), computerized Digit Symbol Substitution Task (McLeod et al. 1982 and Continuous Performance Task (CPT; Martin et al. 2007 ) also were completed.
Statistical analysis
All measures were analyzed initially as raw time course data using a two-factor analysis of variance (ANOVA with Proc Mixed to account for any missing data; dose x time). SAS 9.2 software for Windows was used and results were considered significant when p<0.05. The online physiological measures, collected at 1-minute intervals, were averaged across time to yield 30-minute intervals. Dunnett's post hoc tests were used to compare scores between active doses and placebo across time points. When a significant interaction of dose and time was observed, significant main effects are not reported. Outcomes with only a significant main effect of time also are not reported.
In addition, individual peak scores analyses (either nadir or maximum depending upon the direction of effects, with the exception of pupil diameter, which was analyzed as both nadir and maximum) were completed using a one-factor ANOVA (dose). Raw values were used to calculate peak, with the exception of oxygen saturation, heart rate, blood pressure, respiration rate, and expired CO 2 , which were calculated as change from baseline. Dunnett's post hoc tests were used to compare peak scores between active doses and placebo.
Drug identification data were analyzed by determining the most commonly identified drug (i.e., the mode) for each dose condition. If the drug was identified as an opioid, the mode for the type of opioid also was determined.
Results
Participants
Of the 15 participants screened for the study, 13 were qualified, and admitted and ten completed the study. One of those screened was lost to follow up, and one failed to meet inclusion/exclusion criteria due to opioid physical dependence. Three participants left early after admission for reasons unrelated to the protocol: One was medically discharged due to development of a toothache, one left due to craving opioids and one left due to childcare problems. Only data from the ten completers (six male and four female) were analyzed. Nine were Caucasian, and one was of mixed race (Asian and Caucasian). Participants were 37± 8 (mean±SD) years old. All reported current recreational use of prescription opioids with a mean of 9 days using per month (±2). The most common opioids used were oxycodone and hydrocodone. One participant also had used heroin in the month preceding screening. Eight participants were daily cigarette smokers and five reported current alcohol use (10±7 days out of the past 30). Other drug use in the 30 days prior to screening reported on the Addiction Severity Index and other screening instruments was common. Seven participants reported use of benzodiazepines (3±3 days out of the past 30), five reported marijuana use (19±14 days out of the past 30), four reported cocaine use (7±4 days out of the past 30), and one reported amphetamine use (4 days out of the past 30). No subject was physically dependent on any drug requiring detoxification.
Time course
Physiological measures As shown in the top panels of Fig. 1 , tramadol and hydromorphone produced doserelated decreases in pupil diameter, with the highest dose of tramadol and both doses of hydromorphone decreasing pupil diameter significantly compared to placebo. Miosis was generally evident within 1-1.5 h of hydromorphone administration (i.e., at times 120-150), but appeared later after the higher doses of tramadol (i.e., 2.5 h after dosing at time 210); in both cases, pupil constriction persisted throughout the 6-h post dosing period of the sessions. The reductions in pupil diameter following tramadol were of much smaller magnitude than those produced by hydromorphone. As shown in the bottom panels of Fig. 1 , naltrexone blocked the miosis produced by 350 mg tramadol and 16 mg hydromorphone, and, while not statistically significant, tramadol actually increased pupil diameter (i.e., mydriasis) after naltrexone pretreatment compared to placebo. Naltrexone also blocked the miosis produced by the lower tramadol dose and hydromorphone dose (data not shown).
Significant main effects of dose (F 11,99 02.0, p00.03) and time (F 14,126 03.5, p<0.0001) were observed for respiration 
Adjectives (subjective and observer)
rate, but there were no consistent differences detected in post hoc testing between placebo and active doses (data not shown). There were no significant findings for the other physiological measures. However, one notable finding, which was not analyzed statistically, was that subjects vomited more often during sessions testing higher doses of tramadol compared to sessions testing hydromorphone. Specifically, across all 120 sessions in the study, subjects vomited in a total of 12 sessions. Vomiting occurred in seven sessions following the two higher tramadol doses combined with naltrexone, four sessions following the two higher tramadol doses combined with placebo, and one session following the high hydromorphone dose combined with placebo.
Subject-and observer-rated measures Time-dependent increases were observed on VAS ratings of "Liking" after administration of the high tramadol and hydromorphone doses relative to placebo, although the effects of tramadol were of lower magnitude than those of hydromorphone (Fig. 2 , top left panel). These effects were evident 1 h after dosing (i.e., at time 120) and ratings were elevated throughout the remainder of the session. Ratings produced by 350 mg tramadol were generally no longer statistically different from placebo with naltrexone pretreatment; however, the absolute time course and magnitude of ratings were quite similar to the effects of 350 mg tramadol in combination with placebo. The lack of a statistically significant effect for the combination of 350 mg tramadol and naltrexone could be due to increased inter-individual variability. Naltrexone completely blocked ratings of "Liking" produced by 16 mg hydromorphone. The lower tramadol and hydromorphone doses were placebo-like after placebo and naltrexone pretreatment (data not shown). A similar pattern of effects was observed for 350 mg tramadol combined with naltrexone for ratings of "Drug Effect" (data not shown), "High," and "Good Effects," as well as Street Value (Fig. 2 ). An interaction of dose and time (F 154,1386 01.3, p<0.01) was observed for "Bad Effect" ratings with high-dose tramadol transiently increasing "Bad Effect" ratings relative to placebo after placebo pretreatment, but generally not after naltrexone pretreatment (data not shown). "Bad Effect" ratings also were elevated relative to placebo when the intermediate dose of tramadol was combined with naltrexone (data not shown). Statistically significant outcomes were observed on the Withdrawal Scale (main effects of dose and time; F 11,99 02.2, p00.02 and F 14,126 05.9, p<0.0001, respectively) and ratings of "Abdominal Pain" (main effect of dose F 11,99 02.7, p0 0.004), "Bad," "Sick," "Heavy or Sluggish Feeling," "Dry Mouth" (main effects of dose and time; F 11,99 values>2.1, p<0.05 and F 14,126 values > 2.3, p < 0.05, respectively), "Flushing," "Twitch," and "Turning of Stomach" (interaction of dose and time; F 154,1385 >1.4, p≤0.001). Low dose tramadol and hydromorphone were placebo-like for all items after both placebo and naltrexone pretreatment (data not shown). Relative to placebo, high dose tramadol and hydromorphone increased ratings of "Dry Mouth" after placebo, but not naltrexone, administration (data not shown). These doses generally produced no significant effects on the Withdrawal Scale or individual items from the adjective checklist after placebo pretreatment, but naltrexone enhanced the effects of 175 and 350 mg tramadol on those measures compared to placebo. Supplementary Figure 1 shows representative ratings for 175 and 350 mg tramadol and 16 mg hydromorphone for "Sick," "Turning of Stomach," and "Heavy or Sluggish Feeling." No significant dose-related main effects or interactions were observed for the subject-or observer-rated agonist scales.
Ocular and performance tasks There were no significant effects on these measures. Table 2 presents the average nadir or maximum values for outcomes with statistically significant findings from peak analyses.
Peak effects
Physiological measures Compared to placebo, tramadol (350 mg), and both hydromorphone doses decreased nadir pupil diameter after placebo but not naltrexone pretreatment. Both hydromorphone doses decreased maximum pupil diameter relative to placebo, which was blocked by naltrexone pretreatment. Significant mydriasis was observed when the high tramadol dose was combined with naltrexone compared to placebo. High-dose tramadol increased maximum expired CO 2 and both high-dose tramadol and hydromorphone decreased nadir oxygen saturation (all change from baseline scores), compared to placebo, following placebo but not naltrexone pretreatment. An effect also was observed on systolic blood pressure (change from baseline), but post hoc testing revealed no active versus placebo (F 11,99 >2.3, p<0.05) and time (F 14,126 >5.5, p<0.0001) for "Liking," "Good Effects," and "High". A significant interaction of dose and time (F 143,1287 01.62, p<0.0001) was observed for street value. All other details are the same as for Fig. 1 differences. No significant effects were observed for other physiological measures.
Subject-and observer-rated measures Significant dose effects were observed on several subject-and observer-rated measures (Table 2) . Compared to placebo, hydromorphone (16 mg) increased ratings on VAS ratings (i.e., "High," "Drug Effect," "Good Effect," and "Liking," Opioid Agonist Scale) and Street Value; naltrexone blocked these effects. Tramadol (350 mg) increased peak Opioid Agonist Scale ratings (mean peak, 12.1) following placebo pretreatment that were similar in magnitude to hydromorphone 16 mg (mean peak, 13.3); this test condition also resulted in increased ratings of "Bad Effect," "Turning of Stomach," "Abdominal Pain," "Dry Mouth," and "Relaxed" that were not observed after hydromorphone 16 mg. Tramadol (350 mg) with naltrexone pretreatment increased "Drug Effect" ratings and significantly increased unpleasant feelings that, with the exception of "Turning of Stomach" were different than those observed when this dose was combined with placebo (i.e., "Flushing" and "Sick"). Compared to placebo, the intermediate tramadol dose produced no significant effects following placebo pretreatment but increased ratings of "Bad Effects" and "Turning of Stomach" after naltrexone pretreatment. A significant effect also was observed on the Opioid Withdrawal Scale, but post hoc testing revealed no active versus placebo differences.
Ocular and performance tasks A significant effect of dose was observed for nadir hits and misses on the CPT (Table 2) task only, whereby tramadol 350 mg with naltrexone decreased hits and increased misses.
Drug Identification
Only high-dose tramadol and hydromorphone given with placebo pretreatment were identified as an opioid. The mode drugs identified following tramadol were tramadol and hydromorphone, whereas hydromorphone was identified most commonly as hydromorphone. All other dose conditions, including doses combined with naltrexone, were identified as placebo.
Discussion
The primary findings of this experiment were (1) hydromorphone produced prototypic mu opioid agonist-like effects (e.g., miosis, increased ratings of "Liking") that were dose dependent and were blocked by naltrexone, (2) tramadol produced some effects consistent with mu opioid receptor activation (e.g., miosis, increased ratings of "Liking"), which were of reliably lower magnitude compared to hydromorphone despite the testing of supratherapeutic doses, but also increased ratings of "Bad Effects," (3) naltrexone blocked tramadol-induced physiological effects (e.g., miosis; reduced oxygen saturation) and unveiled pharmacodynamic effects consistent with tramadol's monoaminergic activity (i.e., mydriasis, increased ratings of "Flushing" and "Sick," increased vomiting), and (4) naltrexone pretreatment attenuated, but did not completely block, the positive subjective effects of tramadol observed over time (e.g., "Liking," "Good Effects"), which is in contrast to the complete blockade of the positive subjective effects of hydromorphone by naltrexone.
Hydromorphone (16 mg) alone, the positive opioid control condition, reliably produced prototypic opioid effects, which were completely blocked by naltrexone, consistent with previous work (Preston and Bigelow 1993; Schuh et al. 1999; Walsh et al. 1996 ). These results demonstrate that there was pronounced mu opioid agonist blockade produced by the dose of naltrexone employed here (50 mg, p.o.), validating the experimental method.
The onset of subjective effects of tramadol occurred within approximately 1 h of dosing, consistent with the pharmacokinetic profile of the parent drug, whereas the miotic effects of tramadol appeared later (i.e., within approximately 2.5 h), which is more consistent with the time action profile of M1 (i.e., the T max of M1 is approximately 2 h after dosing; Liao et al. 1992; Lintz et al. 1986; Rouini et al. 2006) . These findings may suggest that the parent drug is responsible for producing the early reported subjective profile, while M1 is responsible for producing miosis as previously suggested (Lofwall et al. 2007 ). Other outcomes observed herein with tramadol under the condition of naltrexone blockade further support this suggestion. For example, for 350 mg tramadol, naltrexone blocked miosis, and mydriasis occurred (see Table 2 ), which on visual inspection, appeared to occur within 1 h after tramadol administration in contrast to the later emergence of miosis with tramadol alone (see Fig. 1 ).
Naltrexone only partially attenuated the time course and magnitude of most of the positive subjective effects of tramadol (e.g., "Liking," "Good Effects," in Fig. 2 ). This finding, in combination with the early onset of tramadol subjective effects (consistent with the parent drug kinetics), suggest that these effects may not be mediated entirely by action at the mu opioid receptor. There is a striking similarity of the time course and magnitude of subjective effects produced by high-dose tramadol following placebo and naltrexone, which is in contrast to the time course results for high-dose hydromorphone following placebo and naltrexone (see Fig. 2 ). These results support the idea that there may be a non-mu mechanism of action, in addition to mu opioid activity, which contributes to the overall constellation of positive subjective effects of this tramadol dose. Interestingly, while neither tramadol nor naltrexone alone significantly increased scores on the Opioid Withdrawal Scale or items sensitive to norepinephrine or serotonin reuptake inhibition (e.g., "Flushing"), the naltrexone-tramadol combination did increase scores on these measures. Increases on the Withdrawal Scale are not likely due to actual opioid withdrawal as these were not physically dependent individuals, but rather are attributable to symptoms of opioid withdrawal that also overlap with monoamine reuptake blockade effects, such as "Turning of Stomach" and "Flushing" (e.g., flushing is similar to hot flashes that can be part of opioid withdrawal). Vomiting occurred most commonly in naltrexone-tramadol sessions; gastrointestinal side effects such as nausea and vomiting are not uncommon side effects of serotonin reuptake inhibitors, particularly if started at a high dose without an initial dose run-up (e.g., fluoxetine). Furthermore, norepinephrine reuptake inhibitors cause mydriasis, which was only observed for tramadol after naltrexone administration (Matouskova et al. 2011 ; see also Laeng et al. 2012) . Taken together, these outcomes suggest that naltrexone blockade allowed the serotonergic and noradrenergic effects of tramadol to emerge or to become more evident and/or enhanced.
These data suggest that high doses of tramadol produce a signal of abuse potential, with increases on some prototypic measures such as "Liking" and increased Street Value ratings but that this effect is seen only at supratherapeutic doses for which the profile also includes negative subjective effects (i.e., increased ratings of "Bad Effects"). Moreover, tramadol was distinguishable from hydromorphone by its lower potency (and likely lower intrinsic activity; Volpe et al. 2011) , its slower time to reach maximum physiological effect, and the participants' ability to distinguish correctly between the two drugs. These findings are generally concordant with conclusions in the literature that tramadol has reduced abuse potential relative to prototypic opioid analgesics (e.g., Epstein et al. 2006; Raffa 2008) .
Naltrexone pretreatment resulted in an emergence of negative subjective effects for the intermediate tramadol dose (e.g., peaks for "Bad Effects," "Turning of Stomach") and changed the negative subjective effects observed after the high tramadol dose (e.g., peaks for "Flushing," "Sick") relative to those observed following placebo pretreatment (e.g., peaks for "Bad Effect," "Dry Mouth"), which indicate that the relative degree and type of bad effects of tramadol were altered by administration of an opioid antagonist. This outcome is supportive of previous research implicating the mu opioid receptor in several of the behavioral effects of tramadol (Filip et al. 2004; Lanier et al. 2010; Lofwall et al. 2007; Ren and Zheng 2000; Tzschentke et al. 2002) . For example, in one human laboratory study, naloxone administration precipitated withdrawal in tramadol-maintained subjects (Lanier et al. 2010) . In another study, while tramadol produced negative effects comparable to those observed here, it also suppressed withdrawal among morphine-maintained subjects in a time-dependent manner consistent with the pharmacokinetic profile of M1 (Lofwall et al. 2007 ). These data indicate that some effects of tramadol/M1, particularly those related to opioid physical dependence and withdrawal suppression, are likely mediated by opioid receptors. However, in contrast to prevailing opinion, because naltrexone pretreatment did not completely block the positive, abuse-related subjective effects of 350 mg tramadol, unlike the complete attenuation that was observed in the positive control condition, it is possible that its subjective profile of effects is not wholly attributable to mu opioid receptor activation. This conclusion is inconsistent with the results of preclinical studies implicating the mu opioid receptor in the rewarding effects of tramadol (Ide et al. 2006; Tzschentke et al. 2002) . Those studies suggest that the conditioned place preference effects of tramadol are (1) reduced in mu opioid receptor knockout mice relative to wild-type mice (Ide et al. 2006 ) and (2) attenuated by naloxone administration (Tzschentke et al. 2002) . The finding also is inconsistent with reports that neither serotonin nor norepinephrine reuptake inhibitors have abuse potential (Heil et al. 2002; Jasinski et al. 2008; Yen and Fuller 1992) . It is possible that tramadol produces positive subjective effects through some other pharmacological mechanism. For example, drugs that block reuptake of serotonin or norepinephrine also often interact with the dopamine transporter (e.g., Daws 2009 ) and dopamine reuptake blockade is associated with abuse-related subjective effects (Volkow et al. 1997) ; however, tramadol has not been shown to block dopamine reuptake (Raffa et al. 1992) . Overall, the present findings and extant literature lend support to the conclusion that tramadol produces its effects, including those related to abuse liability, through mixed activation of mu opioid and monoamine receptors.
In this study, there were some discrepancies between time course and peak effect statistical outcomes, particularly for positive subjective effects of tramadol (e.g., tramadol significantly increased ratings of "Good Effects" after placebo and naltrexone in the time course, but not the peak effect, analysis). Following placebo and naltrexone pretreatment, tramadol did increase peak effect ratings for positive subjective effects, with higher magnitude ratings observed in the tramadol/naltrexone conditions, but these outcomes failed to reach statistical significance. This failure to reach significance relative to placebo could be due to the reduced degrees of freedom in the peak effect analyses, which in turn reduced statistical power to detect an effect with post hoc testing, or it could be due to increased variability observed after tramadol dosing relative to what was observed following hydromorphone adminstration. This individual variability in response, indicated by the relatively large error bars in the time course figures, could be related to difference in genotypes (which were not tested here) as polymorphisms in CYP2D6 have been shown to differentially alter the response to tramadol (Matouskova et al. 2011) . However, the impact of individual variability is partially obviated by the use of a within-subject design.
There are several other aspects of the study that warrant further consideration. First, this experiment only used opioid receptor blockade to study the neuropharmacology of tramadol. Future research could test noradrenergic or serotonergic antagonists combined with tramadol to demonstrate more definitively whether these neurotransmitter systems are critical to the positive subjective effects observed here. Second, this study used only one oral naltrexone dose (50 mg). This dose results in near complete blockade of mu opioid receptors (Lee et al. 1988 ) and was sufficient to block the effects of hydromorphone and attenuate the physiological effects of tramadol. However, it is possible that an even higher dose may be needed to produce complete blockade of tramadol's mu opioid effects, as previous studies have shown that higher antagonist doses are needed to block the effects of drugs with lower intrinsic activity relative to full agonists (e.g., Eissenberg et al. 1996; Lanier et al. 2010; Martin et al. 1976; Schuh et al. 1996) . Because a higher opioid antagonist dose was not tested in this study, the receptor systems mediating the positive subjective effects of tramadol cannot be completely determined from our results. Moreover, although tramadol and naltrexone are selective for the mu opioid receptor, they also have affinity for kappa and delta opioid receptors so the specific receptor mediating the opioid-like effects or blockade of tramadol cannot be completely elucidated (Ananthan et al. 1999; Lai et al. 1996; Raffa et al. 1992; Takemori et al. 1988; Volpe et al. 2011; Walsh et al. 2008a ). Third, the drug identification data are confounded by the disclosure in the consent document of the drugs under study, a University of Kentucky IRB requirement, so subjects may have been biased to select tramadol or hydromorphone when they identified the drug they received as an opioid. Even with this confound in place, subjects were able to identify hydromorphone correctly, despite having a range of other options (e.g., methadone, morphine, tramadol, oxycodone), but were less able to identify tramadol accurately.
Taken together, these findings show that naltrexone can be used to disentangle the mixed neuropharmacological actions of tramadol. Naltrexone blocked the mu opioid-related physiological effects of tramadol (i.e., miosis, reduced oxygen saturation). It modestly attenuated the magnitude and time course of tramadol's positive subjective effects and revealed pharmacodynamic effects consistent with tramadol's serotonergic and noradrenergic activity. These data suggest that the non-mu opioid actions of tramadol play a role in its subjective profile and may possibly contribute to its abuse potential.
